Clinical trials: Arterial Thromboembolism
PE - Pulmonary Embolism, PE - Pulmonary Thromboembolism
Stent-Retriever for Acute Massive Pulmonary Embolism (SRAME)
To evaluate treatment outcomes of patients diagnosed with pulmonary embolism.
- Trial name
- SRAME (NCT05992168)
- Testing
- Stent-Retriever
- Where
- China
- Volunteers
- 1 people
- Sponsor
- Suzhou Zenith Vascular SciTech Limited
Arterial Occlusive Diseases
Intra-arterial Microplasmin Administration in Patients With Acute Peripheral Arterial Occlusion
The purpose of the trial is to evaluate the safety and efficacy of microplasmin administration in patients with acute peripheral arterial occlusion.
- Trial name
- NCT00123292
- Testing
- Microplasmin
- Where
- Belgium
- Volunteers
- 19 people
- Sponsor
- ThromboGenics
Ischemic Stroke, Ischemia
Biomarkers of Acute Stroke in Clinic
The proposed study will investigate the clinical use of the ISCDX test that may differentiate between diverse stroke etiologies as listed below: Aim 1: Differentiate between cardioembolic and large artery atherosclerotic ischemic…
- Conditions
- Ischemic Stroke, Ischemia, Atrial Fibrillation, Transient Ischemic Attack
- Trial name
- BASIC (NCT03897478)
- Testing
- ISCDX blood test
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Ischemia Care LLC
Atherosclerosis
Study to Gain Insights in Treatment Patterns and Outcomes in Patients With Atherosclerosis Prescribed to Xarelto in Combination With Acetylsalicylic Acid
In this study researchers want to gain more information on treatment patterns of patients treated with Xarelto in combination with acetylsalicylic acid (ASA). Both drugs reduce the risk of blood clots via different pathways.
- Trial name
- XATOA (NCT03746275)
- Testing
- Rivaroxaban (BAY59-7939, Xarelto), Acetylsalicylic acid
- Where
- 18 sites in Argentina, Brazil and 16 more
- Volunteers
- 5,798 people
- Sponsor
- Bayer
Arterial Occlusive Diseases
Study of Alfimeprase's Ability to Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery
The purpose of this study is to directly compare the safety and efficacy of intra-thrombus alfimeprase 0.3 mg/kg with placebo in acute peripheral arterial occlusion (PAO) as measured by a 30 day open vascular free surgery rate.
- Trial name
- NCT00338585
- Testing
- alfimeprase
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- ARCA Biopharma, Inc.
Arterial Occlusive Diseases
Study of Alfimeprase to Rapidly Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery on Leg Arteries
The purpose of this study is to directly compare the safety and efficacy of intra-thrombus alfimeprase 0.3 mg/kg with placebo in acute peripheral arterial occlusion (PAO) as measured by a 30 day open vascular free surgery rate.
- Trial name
- NCT00115999
- Testing
- alfimeprase
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- ARCA Biopharma, Inc.
Vomiting, Cardiovascular Event
CV Events in Emetogenic Chemotherapy
Describe cardiovascular events in a cancer population receiving highly emetogenic chemotherapy (HEC) or moderately emetogenic chemotherapy (MEC).
- Conditions
- Vomiting, Cardiovascular Event, Arterial Thromboembolic Event
- Trial name
- NCT01366599
- Testing
- HEC or MEC
- Volunteers
- 12,058 people
- Sponsor
- GlaxoSmithKline
Deep Vein Thrombosis, Coronary Artery Bypass Surgery
A Study of the Efficacy of Preventive Dosing of Fondaparinux Sodium Versus Placebo for the Prevention of Venous Thromboembolism (VTE) in Patients Undergoing Coronary Bypass Surgery Receiving Routine Mechanical Prophylaxis
This trial is a prospective, single-center Phase II randomized study to demonstrate the superior efficacy of Fondaparinux Sodium subcutaneous injections in patients undergoing CABG surgery (isolated and redo isolated) versus…
- Conditions
- Deep Vein Thrombosis, Coronary Artery Bypass Surgery, Venous Thromboembolism
- Trial name
- NCT00789399
- Testing
- Fondaparinux
- Volunteers
- 78 people
- Sponsor
- Prairie Education and Research Cooperative
Prevention of Arterial and Venous Thrombosis
A Clinical Study of SHR-2004 Injection in Preventing Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty
The purpose of the study is to evaluate the efficacy and safety of SHR-2004 in preventing venous thromboembolism after elective unilateral total knee arthroplasty.
- Trial name
- NCT06825416
- Testing
- SHR-2004 injection, Enoxaparin sodium injection
- Where
- 2 sites in China
- Volunteers
- 1,165 people
- Sponsor
- Beijing Suncadia Pharmaceuticals Co., Ltd
Carotid Stenosis
Evaluation of the TriActiv ProGuard System During Carotid Artery Stenting
The purpose of this study is to evaluate the safety and efficacy of the TriActiv® ProGuard™ System when used during a stent placement in a blockage within the carotid artery in patients considered to be at high risk for…
- Trial name
- NCT00395785
- Testing
- Carotid Stent Implantation, Embolic Protection
- Where
- 34 sites in United States, Germany
- Volunteers
- 400 people
- Sponsor
- Kensey Nash Corporation
Arterial Thromboembolism
A PMCF Study to Confirm the Performance and Safety of the LeMaitre® TufTex Single Lumen Embolectomy Catheter
A post market clinical study to confirm the performance and safety of the LeMaitre® TufTex Single Lumen Embolectomy Catheter on patients undergoing surgical treatment for the removal of arterial emboli and/or thrombi
- Trial name
- SLC (NCT05386277)
- Testing
- TufTex Single Lumen Embolectomy Catheter
- Where
- 3 sites in Belgium, Germany and 1 more
- Volunteers
- 112 people
- Sponsor
- LeMaitre Vascular
Thromboembolism
Study to Evaluate a Single Dose of Apixaban in Pediatric Participants at Risk for a Thrombotic Disorder
CV185118 is a single dose Apixaban PK/PD study in pediatric participants. The objective of this study is primarily to study the PK/PD of Apixaban in pediatric participants at risk for thrombosis
- Trial name
- NCT01707394
- Testing
- Apixaban
- Where
- 27 sites in United States, Australia and 3 more
- Volunteers
- 49 people
- Sponsor
- Bristol-Myers Squibb
Cancer-Associated Thrombosis (CAT)
REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis
This study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on the prevention of Cancer-Associated Thrombosis (CAT) in participants.
- Trial name
- ROXI-CAT-I (NCT07410117)
- Testing
- REGN7508
- Where
- 23 sites in United States, Georgia and 1 more
- Volunteers
- 1,120 people
- Sponsor
- Regeneron Pharmaceuticals
Carotid Artery Disease, Symptomatic Carotid Artery Stenosis
High Coverage CARotid Stenting vs. Medical Management Alone to Prevent EmboliSm From symptomaTic Non-stenotic cARotid Disease (SyNC)
Goal is to analyse the clinical safety and efficacy of the CARESTO® heal Stent within standard clinical routine for the treatment of patients with symptomatic non-stenotic carotid disease (SyNC) and with high-risk plaque features…
- Conditions
- Carotid Artery Disease, Symptomatic Carotid Artery Stenosis, Carotid Artery Stenting, Carotid Plaque Imaging
- Trial name
- CARESTAR (NCT07166731)
- Where
- Germany
- Volunteers
- 536 people
- Sponsor
- Acandis GmbH
Acute Venous and Arterial Thrombotic and Thromboembolic Events, Healthy Volunteers
A Study to Learn About How Safe BAY3018250 is and What Happens to it in Healthy Japanese Men and Adult Participants Aged 18 to 55 Years
Researchers are looking for a better way to treat people who have acute venous and arterial thrombotic and thromboembolic events. These are severe medical problems due to blood clots forming in and blocking blood vessels.
- Trial name
- NCT06562985
- Testing
- BAY3018250 Dose 1, BAY3018250 Dose 2 infusion, BAY3018250 Dose 2 injection
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Bayer
Stroke, Acute, Stroke, Ischemic
Magnetically Enhanced Diffusion for Acute Ischaemic Stroke (MEDIS) Trial
The objective of the MEDIS study is to determine if subjects experiencing an Acute Ischaemic Stroke due to large vessel occlusion, treated with IV tPA combined with the MED procedure have a greater likelihood of recanalisation…
- Conditions
- Stroke, Acute, Stroke, Ischemic, Infarction, Middle Cerebral Artery, Strokes Thrombotic
- Trial name
- MEDIS (NCT03098732)
- Testing
- Magnetically Enhanced Diffusion (MED)
- Where
- 2 sites in United Kingdom
- Volunteers
- 120 people
- Sponsor
- Pulse Therapeutics
Advanced Cancer, Metastatic Cancer
Prevention of Venous and Arterial Thromboembolism, in Cancer Patients Undergoing Chemotherapy, With a Low Molecular Weight Heparin (Nadroparin Calcium)
In this phase III, multicenter study, 1200 patients with lung, breast, gastrointestinal (stomach, colon-rectum, pancreas), ovarian or head and neck cancer undergoing chemotherapy will be randomly assigned (at the beginning of…
- Trial name
- NCT00951574
- Testing
- Nadroparin calcium
- Where
- 46 sites in Italy
- Volunteers
- 1,166 people
- Sponsor
- Italfarmaco
Arterial Thromboembolism, Venous Thromboembolism
Aspiration Thrombectomy Using the Symphony or Prodigy System
The study is designed to evaluate the short-term and long-term clinical performance and safety of the Symphony and Prodigy thrombectomy systems used in endovascular procedures across the peripheral or pulmonary vasculature.
- Conditions
- Arterial Thromboembolism, Venous Thromboembolism, Pulmonary Embolism
- Trial name
- CLEAR-IT (NCT07350499)
- Testing
- Prodigy Thrombectomy System, Symphony Thrombectomy System
- Where
- 13 sites in United States
- Volunteers
- 750 people
- Sponsor
- Imperative Care, Inc.
Intracranial Embolism, Cerebral Thromboembolism
Effect of ARC1779 on Cerebral Microembolism in Patients Undergoing Carotid Endarterectomy
The purpose of this study is to determine, in patients undergoing carotid endarterectomy, the effect of ARC1779 Injection on the number of microembolic signals detected by transcranial Doppler immediately after surgery.
- Conditions
- Intracranial Embolism, Cerebral Thromboembolism, Carotid Stenosis
- Trial name
- NCT00742612
- Testing
- ARC1779 Injection
- Where
- 7 sites in United States, United Kingdom
- Volunteers
- 100 people
- Sponsor
- Archemix Corp.
Lymphoma
Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)
To understand the safety and efficacy of Revlimid® Capsules 2.5 mg and 5 mg (hereinafter referred to as Revlimid) under actual conditions of use in patients with relapsed or refractory adult T-cell leukemia lymphoma (hereinafter…
- Trial name
- NCT03098589
- Testing
- Revlimid
- Where
- Japan
- Volunteers
- 1,149 people
- Sponsor
- Celgene